Colin Stott
Protagenic Therapeutics, Inc.\newAbout Colin Stott
Colin Stott joined Protagenic Therapeutics (now Phytanix Bio) as Chief Operating Officer and as a director effective May 15, 2025, in connection with the Company’s Share Exchange; his COO employment was terminated on August 8, 2025 as part of a restructuring, and he remains on the Board as a non-employee director . Prior to the combination, Stott served as Chief Operating Officer of Alterola Biotech Inc. and acted as “Seller’s Representative” in the Share Exchange transaction documentation .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Protagenic Therapeutics, Inc. (PTIX) | Chief Operating Officer | May 15, 2025 – Aug 8, 2025 | Joined concurrent with Share Exchange; employment terminated in restructuring; remains a director |
| Protagenic Therapeutics, Inc. (PTIX) | Director | From May 15, 2025 (ongoing as of subsequent filings) | Committee assignments not disclosed in reviewed filings |
| Phytanix Share Exchange (PTIX acquisition of Phytanix Bio) | Seller’s Representative | May 15, 2025 | Transaction role for sellers in Exchange Agreement |
External Roles
| Organization | Role | Tenure/Status | Notes |
|---|---|---|---|
| Alterola Biotech Inc. | Chief Operating Officer | In role as of May 2025 (signature pages) | Signed ancillary agreements in connection with PTIX transaction |
Board Governance
- Appointment and status: Stott was appointed to the PTIX Board on May 15, 2025 and remains a director following the August 8, 2025 restructuring .
- Independence and recent executive service: PTIX filings do not disclose an independence determination for Stott; he served as a company executive (COO) until August 8, 2025, which investors should consider when assessing independence for key committees; no committee assignments for Stott were disclosed in the filings reviewed .
- Board reconstitution context: On May 15, 2025, PTIX accepted three director resignations and appointed Barrett Evans (CEO), Colin Stott (COO), and Jennifer Chao as directors; Garo Armen remained Executive Chairman; other directors continued .
- Legacy committee structure before Stott’s appointment (for context): as of January 3, 2025, Audit (Corvese—Chair, Barrage, Wright), Compensation (Barrage—Chair, Corvese, Wright), Nominating (Wright—Chair, Corvese), Science (Buell, Armen, Stein) .
Fixed Compensation
- No salary, target bonus, or director cash retainer specific to Stott is disclosed in PTIX filings reviewed; upon his COO termination on Aug 8, 2025, the company stated any severance or other compensatory arrangements, if applicable, would be disclosed when determined .
Performance Compensation
- No equity grant details (RSUs/PSUs/options), vesting schedules, or performance metric linkages specific to Stott were disclosed in the reviewed filings; the company indicated severance/compensation outcomes related to his COO termination would be disclosed if applicable .
- Director equity framework (company policy): PTIX historically planned to grant each non‑employee director an annual option for 10,000 shares and 1,250 additional shares for each committee chair role, vesting over three years; reimbursement for reasonable travel is provided (policy as of Jan 3, 2025) .
Other Directorships & Interlocks
| Company | Role | Public/Private | Potential Interlock/Notes |
|---|---|---|---|
| Protagenic Therapeutics, Inc. (PTIX) | Director | Public | Appointed following Share Exchange |
| Alterola Biotech Inc. | Chief Operating Officer | Private | Alterola was a seller in PTIX Share Exchange; Stott signed ancillary agreements on Alterola’s behalf |
| Phytanix Bio (transaction capacity) | Seller’s Representative | N/A | Served as Seller’s Representative in the Exchange Agreement |
Expertise & Qualifications
- Operational leadership in biotech: Served as COO at Alterola Biotech; appointed COO at PTIX concurrent with transaction closing, indicating operating and integration experience in early-stage therapeutics portfolios .
- Transaction/process experience: Served as Seller’s Representative for the Share Exchange, indicating familiarity with deal terms and post-closing obligations .
Equity Ownership
- The company’s May 19, 2025 filings state that Stott had no direct or indirect material interest in any existing or currently proposed transaction requiring disclosure under Item 404(a) of Regulation S‑K at the time of his director/COO appointment .
- Beneficial ownership amounts for Stott were not provided in the company’s prior proxy (which pre‑dated his appointment) and were not otherwise disclosed in reviewed filings .
Governance Assessment
- Strengths:
- Domain and operating knowledge: Executive experience at Alterola and short COO tenure at PTIX may support oversight of integration and pipeline reprioritization .
- No disclosed Item 404 related‑party interest at appointment, reducing immediate conflict concerns around the transaction close .
- Watch items / RED FLAGS:
- Recent executive status: Stott’s service as COO until Aug 8, 2025 raises independence considerations for Audit/Compensation/Nominating committee eligibility under typical exchange standards until any cooling‑off period elapses; PTIX has not disclosed committee assignments for Stott in reviewed filings .
- Potential perceived conflicts: He acted as Seller’s Representative in the Exchange and as Alterola’s COO on related agreement signatures, which can create perceived conflicts in any post‑closing matters between PTIX and sellers, despite the company’s statement of no Item 404(a) material interest at appointment .
- Governance flux: Significant Board and management turnover around the May 2025 combination and August 2025 restructuring (including CEO and COO terminations) suggests elevated governance transition risk; continued disclosure of roles, independence determinations, and committee assignments will be important for investor confidence .
Overall signal: Recent executive-to-director transition and transaction-linked roles call for enhanced scrutiny of independence, committee placement, and any post‑closing seller-related matters, even as filings currently report no material related‑party interest and affirm his continuing service as a director .